Literature DB >> 3780838

Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.

A J Scheen, J C Vancrombreucq, J Delarge, A S Luyckx.   

Abstract

The diuretic effects of torasemide and of furosemide were compared in a double blind cross-over study in 13 patients with stable chronic heart failure. Single doses of 10 mg and 20 mg of torasemide and of 40 mg of furosemide were given orally, in a randomized order on 3 consecutive days. In addition, a placebo was administered on the day preceding the 3 active drug treatment days to obtain control data. Each experimental day was divided into three urine collection periods - 0 to 4 h, 4 to 12 h and 12 to 24 h. Urine output, ion excretion and clearance were measured during each of the 3 periods as well as for the 24-h period. Torasemide 20 mg was distinctly more active in each of the 3 collection periods and in the 24-h period than furosemide 40 mg, whereas no significant difference was found between furosemide 40 mg and torasemide 10 mg for most of the experimental data. From 0 to 4 h, both torasemide and furosemide significantly increased the urinary flow rate and the urinary excretion of sodium, chloride and calcium, while they decreased the urinary osmolality when compared to placebo. All the effects persisted in the 4 to 12 h period after torasemide 20 mg in contrast to furosemide, whose effects were limited to the 0 to 4 h period. In the third period (12-24 h), the urine volume fell below the placebo value after furosemide but not torasemide, and only torasemide 20 mg was followed by a persistent decrease in the urine osmolality.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780838     DOI: 10.1007/bf00541465

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.

Authors:  R E Cutler; A W Forrey; T G Christopher; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

2.  Evaluation in man of bumetanide, a new diuretic agent.

Authors:  R Henning; O Lundvall
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

3.  The acute effects of furosemide on acid and electrolyte excretion in man.

Authors:  J B Puschett; M Goldberg
Journal:  J Lab Clin Med       Date:  1968-04

4.  Dual effect of potent diuretics on renal handling of phosphate in man.

Authors:  T H Steele
Journal:  Metabolism       Date:  1971-08       Impact factor: 8.694

5.  Cellular mechanism of the action of loop diuretics on the thick ascending limb of Henle's loop.

Authors:  R Greger; E Schlatter
Journal:  Klin Wochenschr       Date:  1983-10-17

6.  Clinical and pharmacological investigations of the new saluretic azosemid.

Authors:  F Krück; W Bablok; E Besenfelder; G Betzien; B Kaufmann
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

7.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

8.  Absorption and disposition of furosemide in congestive heart failure.

Authors:  D C Brater; R Seiwell; S Anderson; A Burdette; G J Dehmer; P Chennavasin
Journal:  Kidney Int       Date:  1982-08       Impact factor: 10.612

9.  A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers.

Authors:  L Dodion; Y Ambroes; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Pharmacological properties of the new potent diuretic torasemide in rats and dogs.

Authors:  A Ghys; J Denef; J M de Suray; M Gerin; A Georges; J Delarge; J Willems
Journal:  Arzneimittelforschung       Date:  1985
View more
  16 in total

1.  Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

Review 3.  Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

4.  Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure.

Authors:  Matthew Griffin; Veena S Rao; James Fleming; Parinita Raghavendra; Jeffrey Turner; Devin Mahoney; Nicholas Wettersten; Alan Maisel; Juan B Ivey-Miranda; Lesley Inker; Wai Hong Wilson Tang; Francis Perry Wilson; Jeffrey M Testani
Journal:  Am J Cardiol       Date:  2019-09-06       Impact factor: 2.778

Review 5.  Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects.

Authors:  A J Reyes
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.

Authors:  Vic Hasselblad; Wendy Gattis Stough; Monica R Shah; Yuliya Lokhnygina; Christopher M O'Connor; Robert M Califf; Kirkwood F Adams
Journal:  Eur J Heart Fail       Date:  2007-08-24       Impact factor: 15.534

Review 7.  Torasemide. An update of its pharmacological properties and therapeutic efficacy.

Authors:  C J Dunn; A Fitton; R N Brogden
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

8.  Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects.

Authors:  Y Ambroes; I Ronflette; L Dodion
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Authors:  D C Brater
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

10.  Torasemide in the treatment of patients with cirrhosis and ascites.

Authors:  P Gentilini; G Laffi; G La Villa; V Carloni; M Foschi; R G Romanelli; F Marra
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.